to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. The company possesses multiple proprietary siRNA delivery technology platforms including AtuPLEX, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. A second, complementary delivery technology known as PolyTran™ offers safe and effective systemic administration using a library of novel peptide-based
biodegradable polycationic polymers. Additionally, the company has a platform of novel short interfering RNA (siRNA) molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including increased stability against nuclease degradation. Silence's unique RNAi assets also include structural features for a next generation of RNAi molecules and additional proprietary siRNA sequences against more than 50 highly valued oncology and other disease targets.
Silence has built a strong and diverse intellectual property portfolio covering all essential areas of RNAi therapeutic development including multiple proprietary siRNA delivery technologies, potent siRNA sequences and key siRNA structural and chemical features, as well as specific high-value disease targets. This portfolio includes an exclusive license to the Zamore patent family from the University of Massachusetts, which covers broad structural features of siRNA design for more potent next generation siRNA sequences.
Silence Therapeutics is headquartered in London, UK, with research and development operations in Berlin and Palo Alto, CA.
This press release includes forward-looking sta
Page: 1 2 3 Related biology technology :1
|SOURCE Silence Therapeutics PLC|
Copyright©2010 PR Newswire.
All rights reserved
. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer2
. Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent3
. Silence Therapeutics Patent Update4
. Silence Obtains Important Patent Protection for Lead Internal Development Compound, Atu0275
. Organizational Changes at Silence Therapeutics6
. Silence Therapeutics Announces Successful Opposition of Glover Patent7
. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry8
. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery9
. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma10
. Oxygen Biotherapeutics, Inc. Outlines Plans for New Products During Investor Conference Presentation11
. The Honorable Tommy G. Thompson Joins the United Therapeutics Corporation Board of Directors